ArticleArthritis care & research2026
Hydroxychloroquine Use, Preeclampsia, and Preterm Delivery Complications in Systemic Lupus Erythematosus Pregnancies: Is There a Protective Effect?
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveSystemic lupus erythematosus (SLE) increases the risk of adverse pregnancy outcomes, including preeclampsia and preterm delivery. Hydroxychloroquine (HCQ), widely used to manage SLE, has shown mixed associations with pregnancy outcomes. We investigated the association between HCQ use and risks of preeclampsia/eclampsia and preterm delivery, accounting for maternal covariates in a population-based cohort of SLE pregnancies.
methodsWe studied 847 singleton pregnancies among 597 publicly insured women with SLE in the British Columbia Perinatal Data Registry (mean ± SD maternal age 33.1 ± 4.6 years; 43% nulliparous). SLE was identified before pregnancy, and HCQ exposure during pregnancy was defined using multiple approaches, including ≥2 fills or ≥60 days' supply during the 20 weeks of pregnancy. Modified Poisson regression estimated risk ratios (RRs) and 95% confidence intervals (CIs) using propensity scores to address confounding. Stratified analyses examined effect modification. For preterm delivery, we conducted a time-to-event analysis using a Cox proportional hazards model. Multiple sensitivity analyses explored definitions of SLE, HCQ exposures, and outcomes.
resultsPregnancies with ≥2 fills or ≥60 days' supply compared to no fills had an adjusted RR of 0.92 (95% CI 0.47-1.80). Results were similar when expanding the exposure window to include three months preconception. We found no association across different definitions for preterm delivery. The stratified analyses results showed no appreciable differences.
conclusionEarly pregnancy HCQ use in patients with SLE was not significantly associated with reduced risk of preeclampsia or preterm delivery. Further studies with larger cohorts are needed to clarify these associations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.